keyword
MENU ▼
Read by QxMD icon Read
search

CSII

keyword
https://www.readbyqxmd.com/read/29780415/comparison-of-efficacy-and-safety-of-lispro-and-aspart-evaluated-by-continuous-glucose-monitoring-system-in-patients-with-newly-diagnosed-type-2-diabetes
#1
Bing-Li Liu, Guo-Ping Yin, Feng-Fei Li, Yun Hu, Jin-Dan Wu, Mao-Yuan Chen, Lei Ye, Xiao-Fei Su, Jian-Hua Ma
Objective: To compare the effect of the rapid-acting insulin analogues (RAIAs) aspart (NovoRapid) and lispro (Prandilin) on glycemic variations by continuous glucose monitoring system (CGMS) in patients within newly diagnosed type 2 diabetes mellitus (T2DM) receiving continuous subcutaneous insulin infusion (CSII) and metformin intensive therapy. Methods: This is a single-blind randomized controlled trial. A total of 110 patients with newly diagnosed T2DM and with hemoglobin A1c (HbA1c%) above 9% was hospitalized and randomly divided into two groups: group Asp (NovoRapid group) and group Lis (Prandilin group)...
2018: International Journal of Endocrinology
https://www.readbyqxmd.com/read/29753586/cost-effectiveness-of-sensor-augmented-pump-therapy-in-two-different-patient-populations-with-type-1-diabetes-in-italy
#2
A Nicolucci, M C Rossi, D D'Ostilio, A Delbaere, S de Portu, S Roze
BACKGROUND AND AIMS: Sensor-augmented pump therapy (SAP) combines real time continuous glucose monitoring (CGM) with Continuous Subcutaneous Insulin Infusion (CSII) and provides additional benefits beyond those provided by CSII alone. SAP with automated insulin suspension provides early warning of the onset of hyperglycemia and hypoglycemia and has the functionality to suspend insulin delivery if sensor glucose levels are predicted to fall below a predefined threshold. Aim of this study was to assess the cost-effectiveness of SAP with automated insulin suspension versus CSII alone in type 1 diabetes...
April 5, 2018: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/29745917/which-factors-may-affect-the-quality-of-life-in-patients-with-type-1-diabetes-mellitus-using-the-medtronic-veo-continuous-subcutaneous-insulin-infusion-pump
#3
P Thomakos, G Panagopoulos, O Kepaptsoglou, C Zoupas, A Mitrakou
Continuous Subcutaneous Insulin Infusion (CSII) is considered an effective therapeutic approach to the treatment of patients with Type 1 Diabetes Mellitus (T1DM). Literature offers limited information regarding the quality of life (QoL) in patients using CSII. The aim of the study was to investigate the impact of diabetes related factors on the QoL of patients with T1DM on CSII treatment, in a Greek urban population. A cross-sectional study was conducted on 80 patients with T1DM using CSII. [(Mean±SD) age: 35...
April 2018: Georgian Medical News
https://www.readbyqxmd.com/read/29741925/glycemic-control-in-adult-type-1-diabetes-patients-with-insulin-glargine-insulin-detemir-or-continuous-subcutaneous-insulin-infusion-in-daily-practice
#4
Päivi Rautiainen, Hilkka Tirkkonen, Tiina Laatikainen
BACKGROUNDS: This study aims to compare glycemic control of persons with type 1 diabetes using multiple daily injections (MDI) with insulin glargine versus insulin detemir or with continuous subcutaneous insulin infusion (CSII) in daily practice. SUBJECTS AND METHODS: All adult individuals with type 1 diabetes (n = 1053) were identified from the electronic patient database in North Karelia, Finland. The persons' individual data for insulin treatment, diabetic ketoacidosis (DKA), and hemoglobin A1c (HbA1c) measurements during the year 2014 were obtained from medical records...
May 9, 2018: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29733870/prevalence-and-geographical-distribution-of-insulin-pump-therapy-in-the-central-denmark-region-and-its-association-with-metabolic-parameters
#5
Ulla Kampmann, Lene Ring Madsen, Lasse Bjerg, Daniel R Witte, Kjeld Hasselstrøm, Torben Østergård, Kirsten Alstrup, Marianne Kleis Møller, Dorrit Dylmer, Klavs Würgler Hansen
AIMS: Insulin treatment in type 1 diabetes encompasses multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII). Both population-based studies and comparative studies regarding CSII use are sparse. The aim of the current study was to describe the prevalence and distribution of CSII use among adults with type 1 diabetes in the Central Denmark Region and to compare metabolic control in CSII-treated patients to those treated with MDI. METHODS: A database was constructed using the Danish Adult Diabetes Registry in 2014/2015 in combination with an audit of the patients' medical records...
May 4, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29730390/pre-exercise-blood-glucose-affects-glycemic-variation-of-aerobic-exercise-in-patients-with-type-2-diabetes-treated-with-continuous-subcutaneous-insulin-infusion
#6
Yun Hu, Dan-Feng Zhang, Lu Dai, Zheng Li, Hui-Qin Li, Feng-Fei Li, Bing-Li Liu, Xiao-Juan Sun, Lei Ye, Ke He, Jian-Hua Ma
AIMS: Considering the insulin sensitivity may increase by exercise particularly in patients with type 2 diabetes (T2D), glycemic variation during exercise needs to be studied when the patients are treated with insulin. This study aimed to explore the influence factors of the efficacy and safety of aerobic exercise in patients with T2D treated with Continuous Subcutaneous Insulin Infusion (CSII). METHODS: A total of 267 patients with T2D, treated with CSII, were included...
May 3, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29681173/consensus-statement-on-use-of-continuous-subcutaneous-insulin-infusion-therapy-in-the-hospital
#7
Bithika Thompson, Mary Korytkowski, David C Klonoff, Curtiss B Cook
In May 2017, the Diabetes Technology Society convened a panel of US experts on inpatient diabetes management to discuss the current and potential role of continuous subcutaneous insulin infusion (CSII) therapy in the hospital. The panel (1) discussed evidence for current use of CSII in the hospital, (2) recommended contraindications for use in the hospital, and (3) recommended guidelines to maximize chances for safe use of CSII in the hospital. Panel members agreed that larger, prospective, randomized studies are needed to evaluate safety and efficacy of CSII use in the hospital...
April 1, 2018: Journal of Diabetes Science and Technology
https://www.readbyqxmd.com/read/29679630/high-irisin-levels-are-associated-with-better-glycemic-control-and-bone-health-in-children-with-type-1-diabetes
#8
Maria Felicia Faienza, Giacomina Brunetti, Lorenzo Sanesi, Graziana Colaianni, Monica Celi, Laura Piacente, Gabriele D'Amato, Ernestina Schipani, Silvia Colucci, Maria Grano
AIM: Irisin is a new peptide produced mainly by the skeletal muscle playing an important role both in glucose/energy homeostasis and bone metabolism. Childhood type 1 diabetes mellitus (T1DM) is associated with decreased bone mass. We aimed to evaluate irisin levels in TD1M children and their correlation with bone metabolism and glycaemic control. METHODS: Ninety-six T1DM subjects (12.2 ± 4 years), 56 on multiple daily injections (MDI), 40 on continuous subcutaneous insulin infusion (CSII), and 34 controls were included in the study...
April 19, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29672623/impaired-vibrotactile-sense-in-children-and-adolescents-with-type-1-diabetes-signs-of-peripheral-neuropathy
#9
Erik Ising, Lars B Dahlin, Helena Elding Larsson
OBJECTIVE: To investigate whether multi-frequency vibrometry can identify individuals with elevated vibration perception thresholds (VPTs), reflecting impaired vibrotactile sense, among children and adolescents with type 1 diabetes. METHODS: In 72 pediatric patients with type 1 diabetes, VPTs were evaluated for seven frequencies on two sites of the hand, and five frequencies on two sites of the foot. Z-scores, based on previously collected reference data, were calculated...
2018: PloS One
https://www.readbyqxmd.com/read/29661916/sustained-reduction-in-severe-hypoglycemia-in-adults-with-type-1-diabetes-complicated-by-impaired-awareness-of-hypoglycemia-2-year-follow-up-in-the-hypocompass-randomized-clinical-trial
#10
Stuart A Little, Jane Speight, Lalantha Leelarathna, Emma Walkinshaw, Horng Kai Tan, Anita Bowes, Alexandra Lubina-Solomon, Thomas J Chadwick, Deborah D Stocken, Catherine Brennand, Sally M Marshall, Ruth Wood, David Kerr, Daniel Flanagan, Simon R Heller, Mark L Evans, James A M Shaw
OBJECTIVE: Severe hypoglycemia is a feared complication of type 1 diabetes; yet, few trials have targeted prevention using optimized self-management (educational, therapeutic, and technological support). We aimed to investigate whether improved awareness and reduced severe hypoglycemia, achieved during an intensive randomized clinical trial (RCT), were sustained after return to routine care. RESEARCH DESIGN AND METHODS: Ninety-six adults with type 1 diabetes (29 ± 12 years' duration) and impaired awareness of hypoglycemia at five U...
April 16, 2018: Diabetes Care
https://www.readbyqxmd.com/read/29652893/glucose-sensor-augmented-continuous-subcutaneous-insulin-infusion-in-patients-with-diabetic-gastroparesis-an-open-label-pilot-prospective-study
#11
Jorge Calles-Escandón, Kenneth L Koch, William L Hasler, Mark L Van Natta, Pankaj J Pasricha, James Tonascia, Henry P Parkman, Frank Hamilton, William H Herman, Marina Basina, Bruce Buckingham, Karen Earle, Kjersti Kirkeby, Kristen Hairston, Tamis Bright, Amy E Rothberg, Andrew T Kraftson, Elias S Siraj, Angela Subauste, Linda A Lee, Thomas L Abell, Richard W McCallum, Irene Sarosiek, Linda Nguyen, Ronnie Fass, William J Snape, Ivana A Vaughn, Laura A Miriel, Gianrico Farrugia
Erratic blood glucose levels can be a cause and consequence of delayed gastric emptying in patients with diabetes. It is unknown if better glycemic control increases risks of hypoglycemia or improves hemoglobin A1c levels and gastrointestinal symptoms in diabetic gastroparesis. This study investigated the safety and potential efficacy of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) in poorly controlled diabetes with gastroparesis. Forty-five type 1 or 2 patients with diabetes and gastroparesis and hemoglobin A1c >8% from the NIDDK Gastroparesis Consortium enrolled in a 24 week open-label pilot prospective study of CSII plus CGM...
2018: PloS One
https://www.readbyqxmd.com/read/29651052/management-of-glycemic-variation-in-diabetic-patients-receiving-parenteral-nutrition-by-continuous-subcutaneous-insulin-infusion-csii-therapy
#12
Feng-Fei Li, Wen-Li Zhang, Bing-Li Liu, Dan-Feng Zhang, Wei Chen, Li Yuan, Mao-Yuan Chen, Xiao-Fang Zhai, Jin-Dan Wu, Xiao-Fei Su, Lei Ye, Hong-Yong Cao, Jian-Hua Ma
To compare the continuous subcutaneous insulin infusion (CSII) or insulin glargine based multiple injections (MDI) therapy on glycemic variations in diabetic patients receiving PN outside of intensive care settings. This was a single-center, randomized, open-label trial. Patients with type 2 diabetes (T2D) who were receiving parenteral nutrition (PN) were recruited. After baseline data were collected, recruited patients were then randomized 1:1 to a CSII group or a MDI group. All patients were subjected to a 4-day retrospective Continuous Glucose Monitoring (CGM)...
April 12, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29623593/efficacy-and-safety-of-rapid-acting-insulin-analogs-in-special-populations-with-type-1-diabetes-or-gestational-diabetes-systematic-review-and-meta-analysis
#13
REVIEW
Kirsten Nørgaard, Nithya Sukumar, Snorri B Rafnsson, Ponnusamy Saravanan
INTRODUCTION: To assess the efficacy and safety of three available rapid-acting insulin analogs (insulins lispro, aspart and glulisine, respectively) in pregnant women, children/adolescents and people using continuous subcutaneous insulin infusion (CSII) with type 1 diabetes. METHODS: PubMed, EMBASE and Cochrane Reviews were searched electronically, and their bibliographies examined to identify suitable studies for review and inclusion in a meta-analysis. Eligible studies were randomized controlled trials that reported data on relevant clinical outcomes...
April 5, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29595061/continuous-glucose-monitoring-associated-with-less-diabetes-specific-emotional-distress-and-lower-a1c-among-adolescents-with-type-1-diabetes
#14
Anthony T Vesco, Aneta M Jedraszko, Kimberly P Garza, Jill Weissberg-Benchell
BACKGROUND: Psychosocial impact research of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) among adolescents with type 1 diabetes (T1D) is limited. The present study assesses associations between diabetes technology use on adolescent- and parent-perceived diabetes-specific distress and A1c. METHOD: Adolescents with T1D and parents (N = 1040; primarily mothers) completed measures of diabetes distress. Adolescents were categorized by technology use: CGM Alone, CSII Alone, CGM+CSII, or No Technology...
March 1, 2018: Journal of Diabetes Science and Technology
https://www.readbyqxmd.com/read/29573166/suboptimal-behaviour-and-knowledge-regarding-overnight-glycaemia-in-adults-with-type-1-diabetes-is-common
#15
Christina R Larsson, Andrzej S Januszewski, Rachel T McGrath, Johnny Ludvigsson, Anthony C Keech, Richard J MacIsaac, Glenn M Ward, David N O'Neal, Gregory R Fulcher, Alicia J Jenkins
BACKGROUND: In people with Type 1 diabetes (T1D) nocturnal hypoglycaemia (NH) can be slept through, and can cause seizures, arrhythmias and death. Hypoglycaemia avoidance can induce hyperglycaemia and ketosis. Patient behaviour impacts clinical outcomes and may be changed by education. AIM: To develop and utilise a survey to evaluate patient self-management of overnight glycaemia in adults with Type 1 Diabetes (T1D). METHODS: Adults with T1D attending two Australian tertiary referral diabetes clinics completed a survey about their diabetes self-management and glycaemic control, including their responses to hypothetical pre-bed blood glucose (BG) levels (4-20mmol/L)...
March 23, 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29547046/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-2018-position-statement-on-integration-of-insulin-pumps-and-continuous-glucose-monitoring-in-patients-with-diabetes-mellitus
#16
George Grunberger, Yehuda Handelsman, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, Richard A Haas, Victor L Roberts, Guillermo E Umpierrez
This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there are no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician...
March 2018: Endocrine Practice
https://www.readbyqxmd.com/read/29545258/continuous-subcutaneous-insulin-infusion-vs-multiple-daily-injections-in-pregnant-women-with-type-1-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials-and-observational-studies
#17
REVIEW
Przemyslaw M Rys, Agnieszka H Ludwig-Slomczynska, Katarzyna Cyganek, Maciej T Malecki
BACKGROUND: Randomised controlled trials (RCTs) have shown an advantage of continuous subcutaneous insulin infusion (CSII) over multiple daily injections (MDI) in the general type 1 diabetes mellitus (T1DM) population. RCT data on T1DM management in pregnancy remain limited. OBJECTIVE: We performed a systematic review of both RCTs and non-RCTs evaluating CSII vs MDI in T1DM-complicated pregnancy. STUDY DESIGN: Electronic databases were searched for studies comparing CSII with MDI in T1DM-complicated pregnancy...
May 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29537377/effectiveness-of-continuous-subcutaneous-insulin-infusion-pump-therapy-during-five-years-of-treatment-on-metabolic-control-in-children-and-adolescents-with-type-1-diabetes-mellitus
#18
Özlem Korkmaz, Günay Demir, Hafize Çetin, İlkin Mecidov, Yasemin Atik Altınok, Samim Özen, Şükran Darcan, Damla Gökşen
OBJECTIVE: To compare continuous subcutaneous insulin infusion (CSII) therapy with multiple daily insulin (MDI) therapy on metabolic control in children and adolescents with type 1 diabetes mellitus (T1DM) over the long term. METHODS: Fifty-two T1DM patients treated with CSII and monitored for at least one year prior to and at least five years following CSII were included. Thirty-eight age and sex-matched MDI controls with a 5-year follow up were recruited. RESULTS: Mean age of the subjects, duration of diabetes and CSII therapy were 17...
June 1, 2018: Journal of Clinical Research in Pediatric Endocrinology
https://www.readbyqxmd.com/read/29530081/evaluating-optimal-utilisation-of-technology-in-type-1-diabetes-mellitus-from-a-clinical-and-health-economic-perspective-protocol-for-a-systematic-review
#19
Anthony Pease, Clement Lo, Arul Earnest, Danny Liew, Sophia Zoungas
BACKGROUND: Technology has been implemented since the 1970s with the hope of improving glycaemic control and reducing the burden of complications for those living with type 1 diabetes. A clinical and cost-effectiveness comparison of all available technologies including continuous subcutaneous insulin infusion (CSII), continuous glucose monitors (CGMs), sensor-augmented pump therapy (including either low-glucose suspend or predictive low-glucose suspend), hybrid closed-loop systems, closed-loop (single-hormone or dual-hormone) systems, flash glucose monitoring (FGM), insulin bolus calculators, and 'smart-device' applications is currently lacking...
March 12, 2018: Systematic Reviews
https://www.readbyqxmd.com/read/29518094/a-randomized-controlled-trial-based-algorithm-for-insulin-pump-therapy-in-hyperglycemic-patients-early-after-kidney-transplantation
#20
Johannes M Werzowa, Marcus D Säemann, Alexander Mohl, Michael Bergmann, Christopher C Kaltenecker, Wolfgang Brozek, Andreas Thomas, Michael Haidinger, Marlies Antlanger, Johannes J Kovarik, Chantal Kopecky, Peter X K Song, Klemens Budde, Julio Pascual, Manfred Hecking
Treating hyperglycemia in previously non-diabetic individuals with exogenous insulin immediately after kidney transplantation reduced the odds of developing Posttransplantation Diabetes Mellitus (PTDM) in our previous proof-of-concept clinical trial. We hypothesized that insulin-pump therapy with maximal insulin dosage during the afternoon would improve glycemic control compared to basal insulin and standard-of-care. In a multi-center, randomized, controlled trial testing insulin isophane for PTDM prevention, we added a third study arm applying continuous subcutaneous insulin lispro infusion (CSII) treatment...
2018: PloS One
keyword
keyword
50725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"